AZD2461: Novel PARP Inhibitor for Breast Cancer Research

Executive Summary: AZD2461 is a poly (ADP-ribose) polymerase (PARP) inhibitor with an IC50 of 5 nM, demonstrating potent cytotoxicity in MCF-7 and SKBR-3 breast cancer cells through PARP-1 inhibition and G2-phase cell cycle arrest (APExBIO). The compound exhibits reduced affinity for P-glycoprotein (Pgp) compared to olaparib, potentially overcoming Pgp-mediated resistance (AZD2281.com). In vivo mouse models show maintained PARP inhibition for hours post-dosing and significant extension of relapse-free survival. AZD2461 is well-tolerated in long-term studies and offers favorable solubility in DMSO and ethanol for laboratory protocols. Product is supplied by APExBIO as catalog A4164, with validated protocols for concentrations of 5–50 μM and incubation times of 48–72 hours (Schwartz 2022).

Biological Rationale

Poly (ADP-ribose) polymerase (PARP) enzymes are critical in DNA repair, particularly in base excision repair pathways. PARP-1 is the predominant nuclear isoform involved in detection and signaling of single-strand DNA breaks. Inhibition of PARP leads to accumulation of DNA damage, especially in cells deficient in homologous recombination repair, such as those carrying BRCA1/2 mutations (Schwartz 2022). Targeting PARP is a validated strategy for selectively sensitizing cancer cells to apoptosis, with clinical applications in breast, ovarian, and prostate malignancies. Resistance to first-generation PARP inhibitors often involves efflux via Pgp transporters, emphasizing the need for molecules with improved pharmacology and resistance profiles.

Mechanism of Action of AZD2461

AZD2461 is a small molecule inhibitor of PARP-1, with a molecular weight of 395.43 Da (C22H22FN3O3). The compound binds to the catalytic domain of PARP-1, preventing poly (ADP-ribose) chain formation and trapping the enzyme at sites of DNA damage. This blocks repair of single-strand breaks, leading to double-strand breaks upon replication. In breast cancer cell lines (MCF-7, SKBR-3), AZD2461 induces a concentration- and time-dependent reduction in viability. Flow cytometry analysis confirms a shift in cell cycle distribution, with increased G2 phase and decreased S phase populations, indicative of G2 arrest. This mechanistic profile is distinct from apoptosis inducers and aligns with the expected activity of PARP-1-targeted agents (APExBIO).

Evidence & Benchmarks

• AZD2461 inhibits PARP-1 activity in vitro with an IC50 of 5 nM, as determined by biochemical enzyme assays (APExBIO).
• In MCF-7 and SKBR-3 breast cancer cells, AZD2461 reduces viable cell numbers in a concentration- and time-dependent manner, with optimal effects at 5–50 μM and 48–72 hours incubation (Schwartz 2022).
• Cell cycle analysis demonstrates G2 phase arrest and reduced S phase proportion after AZD2461 treatment (AZD2281.com).
• In KB1P tumor-bearing mice, AZD2461 administration results in sustained PARP activity inhibition for several hours, with PAR levels returning to baseline by 24 hours (Schwartz 2022).
• AZD2461 exhibits lower affinity for Pgp than olaparib, suggesting an improved profile for overcoming multidrug resistance (olaparib.net).
• Long-term AZD2461 administration in vivo is well-tolerated and extends median relapse-free survival in mouse tumor models (Schwartz 2022).

This article extends the review provided at AZD2281.com by providing updated evidence on in vivo relapse-free survival and pharmacokinetics in BRCA1-mutated models. For a broader mechanistic analysis, see AZD7687.com, which is complemented here by detailed workflow and solubility data. For practical integration and troubleshooting, GW2580.com provides additional context, while this article focuses on benchmarked parameters and resistance mechanisms.

Applications, Limits & Misconceptions

AZD2461 is validated for use in preclinical studies of breast cancer, particularly in models with BRCA1/2 deficiencies or known resistance to first-generation PARP inhibitors. Its low Pgp affinity profile enables studies in multidrug-resistant cell lines and tumor xenografts. The compound is also used in research on DNA repair pathway modulation and synthetic lethality. Key application fields include cell cycle checkpoint analysis, cytotoxicity profiling, and in vivo relapse-free survival studies. However, translation to clinical use requires further toxicological and pharmacokinetic optimization.

Common Pitfalls or Misconceptions

• AZD2461 is not soluble in water; use DMSO (≥16.35 mg/mL) or ethanol (≥45.2 mg/mL with ultrasonic assistance) for stock preparation (APExBIO).
• The compound is not intended for long-term solution storage; solutions should be freshly prepared and used within a short time frame.
• AZD2461 efficacy depends on incubation time and dose; suboptimal conditions may yield false negatives.
• AZD2461 is not a direct apoptosis inducer; its primary action is cytostatic via G2 arrest and DNA repair inhibition.
• Not all multidrug-resistant tumors will respond, particularly those with non-Pgp mediated resistance mechanisms.

Workflow Integration & Parameters

AZD2461 is supplied as a solid by APExBIO (SKU: A4164). It should be stored at -20°C. For in vitro use, dissolve in DMSO or ethanol as specified. Typical experimental concentrations range from 5 to 50 μM, with incubation times of 48 to 72 hours. Cell lines such as MCF-7 and SKBR-3 are validated for cytotoxicity and cell cycle studies. In vivo, dosing schedules should be referenced from published benchmarks (e.g., daily or alternate day dosing in murine models). Monitoring PAR levels, cell viability, and cell cycle phase distribution is recommended to assess efficacy (Schwartz 2022). For detailed protocols, refer to the AZD2461 product page. For troubleshooting or advanced applications, see GW2580.com.

Conclusion & Outlook

AZD2461 represents a significant advance in the portfolio of PARP inhibitors for breast cancer research. Its potent in vitro and in vivo activity, combined with improved pharmacological properties regarding Pgp-mediated resistance, positions it as a valuable tool for dissecting DNA repair pathways and testing novel therapeutic strategies. Continued research will clarify its translational potential, safety profile, and compatibility with existing cancer therapeutics. For further technical and purchasing information, consult the APExBIO AZD2461 listing (A4164).